
The zzso use of intravenous zzso iron as a supplement to zzso agents in patients with zzso anemia is zzso This study was designed to evaluate the efficacy and safety of zzso alpha given with IV iron versus with local standard practice zzso iron or no zzso 

In this zzso randomized, zzso phase III study, zzso patients with zzso zzso and zzso zzso less than 11 zzso received zzso alpha 500 zzso with zzso zzso zzso or without zzso zzso zzso IV iron once every 3 weeks zzso for 16 zzso 

The zzso response rate zzso of patients achieving zzso zzso 12 zzso or zzso increase of zzso 2 zzso from zzso was significantly higher in the IV iron group: zzso versus zzso in the standard practice group zzso of zzso zzso zzso zzso to zzso P zzso zzso Fewer zzso zzso zzso 5 to the end of the treatment zzso occurred in the IV iron group: zzso versus zzso in the standard practice group zzso of zzso zzso zzso zzso to zzso P zzso zzso Both treatments were well tolerated with no notable differences in adverse zzso Serious adverse events related to iron occurred in zzso of patients in the IV iron group and were mostly gastrointestinal in zzso 

zzso of IV iron to zzso alpha zzso in patients with zzso anemia was well zzso resulting in an improved zzso response rate and lower zzso of zzso compared with zzso alpha zzso 

